Mala Jayasundera

Name:	Mala Jayasundera
Affiliation:	University of Cambridge
E-mail:	(only provided to users who are logged into talks.cam)
Last login:	4 Nov 2022, 11:36 a.m.

Public lists managed by Mala Jayasundera

• Cambridge Oncology Seminar Series
• MRC Cancer Unit Seminars
• Type the title of a new list here
• Type the title of a new list here

Talks given by Mala Jayasundera

Obviously this only lists talks that are listed through talks.cam. Furthermore, this facility only works if the speaker's e-mail was specified in a talk. Most talks have not done this.

Talks organised by Mala Jayasundera

This list is based on what was entered into the 'organiser' field in a talk. It may not mean that Mala Jayasundera actually organised the talk, they may have been responsible only for entering the talk into the talks.cam system.

• CANCELLED - “Cancer genomics: from chromatin structure to new therapeutic targets”
• ‘Cell Plasticity in Colon Carcinogenesis’
• ‘Activation of transcription factor Nrf2 as a strategy to restore the cellular redox and protein homeostasis’
• ‘Combining omics data and biological knowledge to understand and treat cancer’
• ‘Why Standard Naming and Pixel-based Contouring/Voluming are important to research in the radiation Oncology area’
• Title to be confirmed
• ‘Next-Generation Biopsies in Gastrointestinal Cancers’
• ‘Mammary epithelial cell fate and tumour initiation at the single cell resolution’
• ‘Multi-dimensional cancer-immune cell interaction during metastasis’
• THIS SEMIAR IS NOW CANCELLED - 'Cell Plasticity in Colon Carcinogenesis'
• ‘Executable Disease Networks: Reconstruction, Topology, Dynamics’
• ‘Cellular Plasticity in Cancer: driving force and therapeutic target’
• ‘Accelerating the translation of mutational signatures'
• "Proton Beam Therapy: Current and Future Provision"
• "Proton Beam Therapy: Current and Future Provision"
• ‘Instituting Molecular Precision in Localised Prostate Cancer - A Cure for All?’
• ‘Tracking metabolic reprogramming in cancers with PI3K/Akt activation’
• Metastasis latency: new molecular insights
• Title to be confirmed
• ‘The role of Mre11 in DNA double strand break repair - myth and facts’
• Satellite RNAs, Heterochromatin and Cancer: A Novel Mechanism of Induction of Breast Cancer by Loss of BRCA1?
• ‘Exploring and exploiting aberrant self-fate programs in leukemia’
• 'Analyses for Rule-Based Models of Cellular Signalling'
• Title to be confirmed
• ‘Alterations of the Polycomb machinery in cancers’
• ‘Non-coding RNA - new roles for old players’
• The interaction between tumor hypoxia and DNA methylation
• CANCELLED - Impact of the Microbiome on cancer and its treatment
• CANCELLED
• "Mechanisms of colon cancer initiation, progression and metastasis"
• "Mechanisms of colon cancer initiation, progression and metastasis"
• Mechanisms of lymphomagenesis: Developmental origins of a paediatric cancer
• Computational Radiotherapy Symposium, 2016: personalised radiotherapy, or how computers can cure cancer
• Computational Radiotherapy Symposium, 2016: personalised radiotherapy, or how computers can cure cancer
• Future of medicines development: capabilities and how industry is evolving and interacting with academia and the NHS
• “Mechanisms of MYC-driven genome instability”
• “Why Determining Pathogenicity in the Age of Precision Medicine, will Require More than Analyzing Genomic Sequences”
• “New Developments in Molecular Imaging of Prostate Cancer”
• “New Developments in Molecular Imaging of Prostate Cancer”
• Innate Genetics and the Tumour Microenvironment Cooperate to Drive Prostate Cancer Aggression
• ‘Combine and conquer: critical pre-clinical and clinical aspects of targeted anti-cancer drugs’
• "Tumor-­induced reprogramming of hepatic metabolism disrupts anti‐tumor immunity”
• Intrinsic and extrinsic determinants of pancreatic cancer stem cells
• Melanoma and the translational cycle of innovation in cancer therapeutics
• Genomics of radiation responses and radiosensitivity
• CANCELLED - "Synergistic effect of radiotherapy and cis-platinum chemotherapy delivered via gold nanoparticles in glioblastoma multiforme"
• "Synergistic effect of radiotherapy and cis-platinum chemotherapy delivered via gold nanoparticles in glioblastoma multiforme"
• ‘Novel dual-action combination therapy enhances angiogenesis whilst reducing tumour growth and spread’
• Interrogating the Architecture of Cancer Genomes
• 'Harnessing hypoxia signalling in cancer'
• 'ECM remodelling during cancer progression'
• DNA damage response: Mechanisms and relevance for cancer development and treatment
• "Designing trials to find the right dose"
• Metastatic Stem Cells, TGF-beta signalling and poor-prognosis in CRC
• Defining treatment paradigms in prostate cancer; the UK as a dominant force - past, present, and future
• Title to be confirmed
• Systems Biology of Cancer
• MYC Oncoproteins act as Epigenetic Modifiers
• “Optimizing Image Guided Radiotherapy for Patient Benefit”
• Explaining the reduction in ovarian cancer mortality 1977 to 2014
• Ovarian Cancer in Transition
• Tracking genomic aberrations of the androgen receptor (AR) in castration-resistant prostate cancer (CRPC)
• “Stratified Medicine in Cancer Therapy - a practical guide”
• Title to be confirmed
• "The role of epigenetic regulators and their therapeutic targeting in Acute Myeloid Leukaemia and haematological malignancies”
• CANCELLED - Lung cancer, biomarkers and unanswered questions - a clinical translational perspective
• “CDD’s new Research Strategy”
• Title to be confirmed
• “Paradigm changes produced by targeted agents in Phase I trials in Oncology. Case studies of a TFbeta inhibitor and a Sonic Hedgehog inhibitor”
• 'Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC): a springboard for renal cancer biomarker development’.
• Precision Cancer Prevention: Trying to use Genomics to Save Lives
• Breast Imaging research in Cambridge
• Personalised Cancer Medicine. How do we get there?
• ‘Vinorelbine In Mesothelioma trial: the rationale’
• "From trials evaluating drugs to trials evaluating treatment algorithms – Focus on the SHIVA trial"
• Title to be confirmed
• “Personalized Medicine in Oncology: The Dutch experience”
• “What can we do to accelerate the discovery of new medicines for patients?”
• Personalized medicine initiative at Gustave Roussy
• Title to be confirmed
• Title to be confirmed
• CANCELLED
• "The Cambridge Breast Cancer Programme"
• CANCELLED - Scottish Collaboration On Translational Research into Renal Cell Cancer, developing a systems medicine approach to personalised treatment
• Spotlight on Cambridge Clinical Trials; Presentations from the American Society of Oncology (ASCO) Annual Meeting 2013
• Target-Based Approach in Early-Phase Clinical Trials in Cancer
• CANCELLED
• Advances in non-surgical treatment for cervix cancer
• Risk and uncertainty in radiotherapy. Why I am the weakest link?
• "Image guidance – benefits and risks"
• Economics of Cancer Medicines
• "Renal Cancer and Oxygen Sensing"
• ‘CLL – from chemotherapy to targeted kinase inhibition’
• “The identification of patients who benefit from targeted therapy in renal cancer”
• Title to be confirmed
• CANCELLED
• Challenges in Implementing Personalized Cancer Medicine: the IGR experience
• Title to be confirmed
• Cellular responses to DNA damage: translating molecular insights towards new cancer therapies
• Mechanisms of Estrogen Receptor Transcription in Breast Cancer
• "Towards personalized medicine in Breast Cancer"
• A genomic Odyssey of predicting drug response: is Ulysses home yet?
• 'Circulating Tumour Cells: Biomarker Utility and Insights to Metastasis'
• cancer
• Understanding Response & Resistance Mechanisms to Targeted Therapy
• Cancer-related inflammation
• Pancreatic cancer: Genetic models to develop novel diagnostic and therapeutic strategies
• "Strategies to enhance effectiveness of Radiotherapy in Pancreatic Cancer"
• ALK Hunting in Colorado - new drugs for lung cancer's new diseases
• CANCELLED
• "Exploiting ASS1 deficiency in the treatment of mesothelioma"
• Lenalinomide & Multiple Myeloma
• Lenalinomide & Multiple Myeloma
• "Thalidomide and its analogues ; How molecules selected for anti-TNFa activity affect so many different pathways with direct binding with Cereblon mediating both anti proliferative and Immunomodulatory functions"
• Title to be confirmed
• "Re Service Reforms in the new Commissioning Landscape"
• Title to be confirmed
• "Resurrection of Thalidomide, the creation of its analogues and Celgene's Translational Medicine Programme'
• "DICER1 and miRNA processing - a novel paradigm in cancer predisposition"
• "Myeloproliferative neoplasms – JAK/STAT signalling and stem cell subversion"
• "Radiotherapy toxicity, Radiogenomics and RAPPER"
• “Imaging Biomarkers in Cancer”
• "Titles to be confirmed"
• Title to be confirmed
• "DICER1 and miRNA processing - a novel paradigm in cancer predisposition"
• Title to be confirmed
• Title to be confirmed
• Title to be confirmed
• Title to be confirmed
• Neo-adjuvant radiochemotherapy in breast cancer
• ‘Genetic predisposition to cancer’
• DNA repair inhibitors in cancer treatment
• ‘Viral and host contributions to cervical carcinogenesis’
• "Advances in Head and Neck Radiotherapy"
• "Developing Medicines for Pancreatic Cancer"
• SOCCAR trial: an update
• “What lessons can we learn from transcriptional evolution in cancer research?”
• CANCELLED
• "Multi-site post-translational modification as a quantitative regulator of transcriptional output during neurogenesis"
• CANCELLED
• Title to be confirmed
• "Somatic Genetics of Human Cancer - Moving Towards Large Scale Resequencing of Cancer Genomes"
• Title to be confirmed
• "The Cambridge breast cancer program- recent progress"
• "FGF-2, S6 kinase 2 and Chemo-resistance in Lung Cancer"
• "FGF-2, S6 Kinase 2 and Chemo-resistance in Lung Cancer"
• Mesothelioma: a disease of our time
• Title to be confirmed
• "Targetting pre-neoplasia in the bronchus"
• Title to be confirmed
• "Leukaemia stem cells: how normal stem cell function is subverted in haematological malignancies"
• Title to be confirmed
• Susceptibility to cancer - what's new?
• “Advances in head and neck radiotherapy”
• Title to be confirmed
• Title to be confirmed
• Title to be confirmed
• Title to be confirmed
• "Advances in Head and Neck Radiotherapy"
• “Breast MRI by the Shutter-Speed Method: Elimination of Unnecessary Breast Biopsies"
• RCC Cinderella comes of age
• "Susceptibility to Cancer - What's New?"
• ‘Genetic predisposition to cancer’
• Targeting NG2 Cells in Glioblastoma
• Title to be confirmed
• "Somatic genetics of human cancer – moving towards large scale resequencing of cancer genomes"
• "Chromosome Translocations and Tumour Suppressors in Breast Cancer"
• "Brain Metastases – a cross cutting theme: Review of the Brain Metastasis Service and Future Research Potential"
• "Imaging Tumour Cell Death"
• "FGF-2, S6 kinase 2 and chemo-resistance in lung cancer"
• “EGFR Mutation Screening in NSCLC”
• "Treating CLL in the Antibody Era"
• Pathway Analysis of Glioblastoma Tissue After Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib – A Phase “0 Trial”
• Title to be confirmed
• Interactions of Epidermal Growth Factor Receptor Inhibition with DNA damage in the treatment of gastrointestinal cancer
• "Breast Radiotherapy - Past, Present and Future"
• "Gastro Intestinal Stroma Tumours (GISTS)"
• Title to be confirmed
• "A New Window of Opportunity in Prostate Cancer"
• "Stem cell identity and mRNA export: unexpected roles of geminin and GANP"
• "Cellular Senescence as a Tumour Suppressor Mechanism, Particular Focus will be on the Autophagy/mTOR Pathway"
• “Macromolecular interactions in the control of chromosome instability”
• Title to be confirmed
• The NCAG Report: Delivering a World Class Chemotherapy Service
• Title to be confirmed
• CANCELLED
• Title to be confirmed
• Title to be confirmed
• "Non-Invasive Diagnosis of Brain Cancer"
• Title to be confirmed
• Title to be confirmed
• Title to be confirmed
• Deciphering the Mammary Epithelial Cell Hierarchy
• Title to be confirmed
• Title to be confirmed
• "The Fine Scale Mapping of Breast Cancer Loci found via GWAS - searching for the Causative Variants"
• CANCELLED
• The prognostic significance of subtypes of breast cancer classified using immunohistochemistry
• Title to be confirmed
• High-throughput Cancer Cell line Screens: Linking Drug Response to Molecular Signatures
• HPV vaccines - will they do their job?
• Title to be confirmed
• Title to be confirmed
• Investigating the interaction of Radiotherapy & Temozolomidefor Glioblastoma
• PREDICT: A NEW UK PROGNOSTIC MODE THAT PREDICTS SURVIVAL FOLLOWING SURGERY FOR INVASIVE BREAST CANCER (GC Wishart, EM Azzato, PDP Pharoah, DC Greenberg, J Rashbass, O Kearins, G Lawrence, C Caldas C, PM Ravdin)
• Title to be confirmed
• The new LAW of microRNA-mediated gene silencing: implications for lung cancer development
• “Intensity modulated radiotherapy for children’s tumours and estimation of the carcinogenic risk”
• ADJUVANT UK: A UK Prognostic Model for Early Breast Cancer that includes Mode of Detection
• "The Arguments for and against Sentinel Node Biopsy (SNB) in Melanoma"
• Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
• "Phospholipase and lysophospholipase D signalling in cancer"
• "Immunostimulatory antibodies in cancer treatment"
• Title to be confirmed
• Title to be confirmed
• Clinical Aspects of Proton Radiotherapy
• Title to be confirmed
• Title to be confirmed